Literature DB >> 32755567

Chemical Biology Toolkit for DCLK1 Reveals Connection to RNA Processing.

Yan Liu1, Fleur M Ferguson2, Lianbo Li1, Miljan Kuljanin3, Caitlin E Mills4, Kartik Subramanian4, Wayne Harshbarger1, Sudershan Gondi1, Jinhua Wang2, Peter K Sorger4, Joseph D Mancias3, Nathanael S Gray2, Kenneth D Westover5.   

Abstract

Doublecortin-like kinase 1 (DCLK1) is critical for neurogenesis, but overexpression is also observed in multiple cancers and is associated with poor prognosis. Nevertheless, the function of DCLK1 in cancer, especially the context-dependent functions, are poorly understood. We present a "toolkit" that includes the DCLK1 inhibitor DCLK1-IN-1, a complementary DCLK1-IN-1-resistant mutation G532A, and kinase dead mutants D511N and D533N, which can be used to investigate signaling pathways regulated by DCLK1. Using a cancer cell line engineered to be DCLK1 dependent for growth and cell migration, we show that this toolkit can be used to discover associations between DCLK1 kinase activity and biological processes. In particular, we show an association between DCLK1 and RNA processing, including the identification of CDK11 as a potential substrate of DCLK1 using phosphoproteomics.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  cancer; doublecortin-like kinase 1; kinase inhibitor; mass spectrometry; phosphoproteomics; signal transduction; structural biology

Year:  2020        PMID: 32755567      PMCID: PMC8053042          DOI: 10.1016/j.chembiol.2020.07.011

Source DB:  PubMed          Journal:  Cell Chem Biol        ISSN: 2451-9448            Impact factor:   8.116


  81 in total

1.  DCLK1 plays an important role in colorectal cancer tumorgenesis through the regulation of miR-200c.

Authors:  Yasaman Mohammadi; Seyed Mohammad Tavangar; Massoud Saidijam; Razieh Amini; Katayoon Etemadi; Fatemeh Karimi Dermani; Rezvan Najafi
Journal:  Biomed Pharmacother       Date:  2018-04-24       Impact factor: 6.529

Review 2.  Eukaryotic DNA topoisomerase II beta.

Authors:  C A Austin; K L Marsh
Journal:  Bioessays       Date:  1998-03       Impact factor: 4.345

3.  Integrated in vivo multiomics analysis identifies p21-activated kinase signaling as a driver of colitis.

Authors:  Jesse Lyons; Douglas K Brubaker; Phaedra C Ghazi; Katherine R Baldwin; Amanda Edwards; Myriam Boukhali; Samantha Dale Strasser; Lucia Suarez-Lopez; Yi-Jang Lin; Vijay Yajnik; Joseph L Kissil; Wilhelm Haas; Douglas A Lauffenburger; Kevin M Haigis
Journal:  Sci Signal       Date:  2018-02-27       Impact factor: 8.192

4.  Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials.

Authors:  Ann Lin; Christopher J Giuliano; Ann Palladino; Kristen M John; Connor Abramowicz; Monet Lou Yuan; Erin L Sausville; Devon A Lukow; Luwei Liu; Alexander R Chait; Zachary C Galluzzo; Clara Tucker; Jason M Sheltzer
Journal:  Sci Transl Med       Date:  2019-09-11       Impact factor: 17.956

5.  Discovery of a benzo[e]pyrimido-[5,4-b][1,4]diazepin-6(11H)-one as a Potent and Selective Inhibitor of Big MAP Kinase 1.

Authors:  Xianming Deng; Qingkai Yang; Nicholas Kwiatkowski; Taebo Sim; Ultan McDermott; Jeffrey E Settleman; Jiing-Dwan Lee; Nathanael S Gray
Journal:  ACS Med Chem Lett       Date:  2011-01-12       Impact factor: 4.345

6.  Pharmacological targeting of the pseudokinase Her3.

Authors:  Ting Xie; Sang Min Lim; Kenneth D Westover; Michael E Dodge; Dalia Ercan; Scott B Ficarro; Durga Udayakumar; Deepak Gurbani; Hyun Seop Tae; Steven M Riddle; Taebo Sim; Jarrod A Marto; Pasi A Jänne; Craig M Crews; Nathanael S Gray
Journal:  Nat Chem Biol       Date:  2014-10-19       Impact factor: 15.040

7.  Discovery of a selective inhibitor of doublecortin like kinase 1.

Authors:  Fleur M Ferguson; Behnam Nabet; Srivatsan Raghavan; Yan Liu; Alan L Leggett; Miljan Kuljanin; Radha L Kalekar; Annan Yang; Shuning He; Jinhua Wang; Raymond W S Ng; Rita Sulahian; Lianbo Li; Emily J Poulin; Ling Huang; Jost Koren; Nora Dieguez-Martinez; Sergio Espinosa; Zhiyang Zeng; Cesear R Corona; James D Vasta; Ryoma Ohi; Taebo Sim; Nam Doo Kim; Wayne Harshbarger; Jose M Lizcano; Matthew B Robers; Senthil Muthaswamy; Charles Y Lin; A Thomas Look; Kevin M Haigis; Joseph D Mancias; Brian M Wolpin; Andrew J Aguirre; William C Hahn; Kenneth D Westover; Nathanael S Gray
Journal:  Nat Chem Biol       Date:  2020-04-06       Impact factor: 15.040

8.  CDK11 Loss Induces Cell Cycle Dysfunction and Death of BRAF and NRAS Melanoma Cells.

Authors:  Rehana L Ahmed; Daniel P Shaughnessy; Todd P Knutson; Rachel I Vogel; Khalil Ahmed; Betsy T Kren; Janeen H Trembley
Journal:  Pharmaceuticals (Basel)       Date:  2019-04-02

9.  Inhibition of Notch signaling reduces the number of surviving Dclk1+ reserve crypt epithelial stem cells following radiation injury.

Authors:  Dongfeng Qu; Randal May; Sripathi M Sureban; Nathaniel Weygant; Parthasarathy Chandrakesan; Naushad Ali; Linheng Li; Terrence Barrett; Courtney W Houchen
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-12-24       Impact factor: 4.871

10.  DCLK1 facilitates intestinal tumor growth via enhancing pluripotency and epithelial mesenchymal transition.

Authors:  Parthasarathy Chandrakesan; Nathaniel Weygant; Randal May; Dongfeng Qu; Harisha R Chinthalapally; Sripathi M Sureban; Naushad Ali; Stan A Lightfoot; Shahid Umar; Courtney W Houchen
Journal:  Oncotarget       Date:  2014-10-15
View more
  5 in total

Review 1.  Tuft and Cancer Stem Cell Marker DCLK1: A New Target to Enhance Anti-Tumor Immunity in the Tumor Microenvironment.

Authors:  Zhiyun Cao; Nathaniel Weygant; Parthasarathy Chandrakesan; Courtney W Houchen; Jun Peng; Dongfeng Qu
Journal:  Cancers (Basel)       Date:  2020-12-17       Impact factor: 6.639

2.  DCLK1 promotes colorectal cancer stemness and aggressiveness via the XRCC5/COX2 axis.

Authors:  Jee-Heun Kim; So-Yeon Park; So-El Jeon; Jang-Hyun Choi; Choong-Jae Lee; Tae-Young Jang; Hyeon-Ji Yun; Yuno Lee; Pilho Kim; Sang Hee Cho; Ji Shin Lee; Jeong-Seok Nam
Journal:  Theranostics       Date:  2022-07-04       Impact factor: 11.600

3.  Targeting Doublecortin-Like Kinase 1 (DCLK1)-Regulated SARS-CoV-2 Pathogenesis in COVID-19.

Authors:  Ram Babu Undi; Jason L Larabee; Adrian Filiberti; Susanna Ulahannan; Sheeja Aravindan; Edana Stroberg; Lisa M Barton; Eric J Duval; Sanjay Mukhopadhyay; James C Henthorn; Darrin Akins; Courtney W Houchen; Mark M Huycke; Naushad Ali
Journal:  J Virol       Date:  2022-08-09       Impact factor: 6.549

4.  Doublecortin-Like Kinase 1 (DCLK1) Is a Novel NOTCH Pathway Signaling Regulator in Head and Neck Squamous Cell Carcinoma.

Authors:  Esther C Broner; Jonathan A Trujillo; Michael Korzinkin; Tejaswini Subbannayya; Nishant Agrawal; Ivan V Ozerov; Alex Zhavoronkov; Lisa Rooper; Nikita Kotlov; Le Shen; Alexander T Pearson; Ari J Rosenberg; Peter A Savage; Vasudha Mishra; Aditi Chatterjee; David Sidransky; Evgeny Izumchenko
Journal:  Front Oncol       Date:  2021-07-16       Impact factor: 5.738

5.  Rapid assessment of DCLK1 inhibitors using a peptide substrate mobility shift assay.

Authors:  Yan Liu; Kenneth D Westover
Journal:  STAR Protoc       Date:  2021-06-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.